## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($84.55)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. How Investors Are Reacting To Zimmer Biomet (ZBH) Dividend Move And OneStep Digital Recovery Partnership**
- Source: Simply Wall Street | 20251219T224103 | Somewhat-Bullish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. recently announced a fourth-quarter 2025 cash dividend of US$0.24 per share and a partnership with OneStep to integrate smartphone-based gait and mobility analytics into its mymobility platform. This collaboration aims to enhance post-surgery orthopedic recovery and remote monitoring, strengthening Zimmer Biomet's connected care ecosystem. While the dividend and partnership don't immediately alter the short-term outlook, the OneStep integration could support wider adoption of premium implants and remote monitoring, reinforcing the long-term thesis that connected care and robotics can provide more stable revenue and margins despite competitive pressures.

**2. Zimmer Biomet will pay investors a cash dividend early next year**
- Source: Stock Titan | 20251217T120155 | Bullish | Relevance: 100%
- Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2025. The medical technology leader will pay the dividend on or about January 30, 2026, to shareholders of record as of December 30, 2025. This move reflects the company's strong financial position and ongoing commitment to returning value to its investors.

**3. Tag Archives: fourth quarter 2025**
- Source: InkFreeNews.com | 20251217T115200 | Bullish | Relevance: 100%
- Zimmer Biomet Holdings Inc. declared a quarterly cash dividend for the fourth quarter of 2025. This article from InkFreeNews.com discusses the dividend announcement.

**4. How Investors Are Reacting To Zimmer Biomet (ZBH) Dividend Move And OneStep Digital Recovery Partnership**
- Source: Simply Wall Street | 20251219T230855 | Somewhat-Bullish | Relevance: 100%
- Zimmer Biomet Holdings recently announced a fourth-quarter 2025 cash dividend of US$0.24 per share and a partnership with OneStep to integrate smartphone-based gait analytics into its mymobility platform. This collaboration aims to enhance post-surgery orthopedic recovery and remote monitoring, reinforcing the company's digital health strategy. While the dividend and partnership don't immediately alter the financial outlook, the OneStep integration is expected to strengthen Zimmer Biomet's connected care ecosystem and potentially support stable revenue and margin trends despite market challenges.

**5. Zimmer Biomet declares quarterly dividend of $0.24 per share By Investing.com**
- Source: Investing.com Nigeria | 20251217T190859 | Somewhat-Bullish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2025, payable on January 30, 2026, to shareholders of record as of December 30, 2025. The company has maintained dividend payments for 14 consecutive years and is considered undervalued by InvestingPro Fair Value metrics. This announcement follows recent developments including FDA clearance for its enhanced ROSA Knee and a collaboration with OneStep to integrate mobility intelligence.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.4% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 9.3% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 10.5x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.7B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 10.5 |
| Current P/E | 10.9 |
| YoY Growth | 4.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.3% to -4.7% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). AM_20 at -4.3% indicates price below own 20MA trend. Underperforming sector by 4.6pp, stock-specific weakness. Below SMA200 (0.91x), long-term trend not supportive. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.65% (CS: 12) | Weak |
| RSI_14 | 37.6 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 0.957x | Below |
| vs SMA50 | 0.939x | Below |
| vs SMA200 | 0.907x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $89.15
- **Stop Loss:** $84.55 (5.2% risk)
- **Target:** $98.35 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 260
- **Position Value:** $23,179.00
- **Portfolio %:** 23.18%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*